Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by SABBOBCATon Feb 26, 2020 3:42pm
48 Views
Post# 30737375

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RBC Cuts Price Target on Theratechnologies to $3 From $3.50

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RBC Cuts Price Target on Theratechnologies to $3 From $3.50Also, isn't it concerning that the IR person may be starting right around the time that bonuses (options) are going to be granted. This is a huge problem and ne D's to be addressed.
SABBOBCAT wrote: "Canadian corporate laws and case laws state that board directors may be held personally liable for their actions of poor decision-making as well as for their unwillingness to act in circumstances where they needed to act. This is because a breach of fiduciary and statutory duties is illegal." I am no expert, but I would argue that granting full bonused given the weak sales, delayed SV launch, delayed trogarzo European launch, and the painfully slow IR hiring process would open up the board to responsibility for not acting on their fiduciary duties. If the BOD keeps status quo with leadership and grant full stock options at these low levels then they have some examining to do.
palinc2000 wrote: Home Depot are advertising a whole range of gaskets....You should take a look 

Bucknelly21 wrote: It's definitely time for change. We have paid the price for the "conviction" of management. At what point should they realize that the strategy and market needs more information from them. It's rather pathetic at this point I'm so so sick of it as most are I'm sure. Spceo while I understand it's not the style could it be presented in a serious but firm suggestion? If they get max compensation I think I will blow a gasket 






Bullboard Posts